Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc demonstrates a promising outlook due to its TRACER platform, which is anticipated to generate significant revenue from collaborations advancing to clinical trials into the 2030s. The company's innovative gene therapies, particularly the VY1706 program, have shown impressive preclinical results, including a 73% reduction in tau messenger RNA and over 50% reduction in protein levels in non-human primates, suggesting strong therapeutic potential with enhanced safety profiles. Additionally, the unique delivery systems employed, such as the NeuroShuttle, have highlighted advantages in durability and central nervous system exposure, positioning the company favorably in the competitive gene therapy landscape.
Bears say
Voyager Therapeutics Inc. has encountered significant challenges, leading to a negative outlook on its stock performance, notably characterized by a lack of substantial revenue generation and ongoing operational losses. The company's research and development expenditures remain high, raising concerns about its financial sustainability, especially as it continues to invest heavily in its gene therapy programs without immediate returns. Additionally, uncertainty surrounding the regulatory approval processes and the commercial viability of its pipeline products further exacerbates the financial risks faced by the company.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares